BioCryst Pharmaceuticals (BCRX) vs Mesoblast (MESO)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
BioCryst Pharmaceuticals (BCRX) has outperformed Mesoblast (MESO) over the past year, gaining 20.9% versus a loss of 22.9%. Over five years, MESO leads with a +22.7% price change compared with -44.5% for BCRX. BioCryst Pharmaceuticals is the larger company by market cap ($2.12 billion vs $1.79 billion), about 1.2 times the size.
On valuation, BioCryst Pharmaceuticals trades at a lower forward P/E (8.8x vs 30.2x for Mesoblast).
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BCRX | MESO |
|---|---|---|
| Share price | $8.29 | $13.75 |
| Market cap | $2.12B | $1.79B |
| 1-day change | -1.31% | -1.36% |
| YTD return | +7.69% | -22.73% |
| 1-year return | +20.86% | -22.94% |
| 5-year return | -44.48% | +22.71% |
| Forward P/E | 8.82 | 30.22 |
| EPS (TTM) | $-1.40 | $-0.44 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $11.22 | $21.50 |
| 52-week low | $6.00 | $13.05 |
| Distance from 52-week high | -26.11% | -36.05% |
| Analyst consensus | buy | buy |
| Avg. price target upside | +150.06% | +169.09% |
| Average volume | 4.11M | 232.53K |
| Shares outstanding | 255.54M | 129.85M |
| Employees | 435 | 108 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- BCRX has outperformed MESO by 43.8 percentage points over the past year.
About BioCryst Pharmaceuticals
BCRX stock →BioCryst Pharmaceuticals, Inc., a biotechnology company, developing and commercializing medicines for hereditary angioedema (HAE) and other rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated and seasonal influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat HAE.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 435 employees
About Mesoblast
MESO stock →Mesoblast Limited, together with its subsidiaries, engages in the development of regenerative medicine products in Australia. The company's proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 108 employees
BCRX vs MESO FAQ
Which is bigger, BioCryst Pharmaceuticals or Mesoblast?
BioCryst Pharmaceuticals (BCRX) is larger, with a market capitalization of $2.12B compared with $1.79B for Mesoblast (MESO).
Which stock has performed better over the past year, BCRX or MESO?
BCRX returned +20.86% over the past 12 months, compared with -22.94% for MESO (price return, excluding dividends). Past performance does not predict future results.
Are BioCryst Pharmaceuticals and Mesoblast in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.